Ibrance (palbociclib) drug profile, 2024?

Ibrance (palbociclib) — Drug Profile (2024)

Generic name: palbociclib
Brand: Ibrance
Drug class: CDK4/6 inhibitor (cyclin-dependent kinases 4 and 6)
Common formulation: oral capsules (typically 75 mg, 100 mg, 125 mg; dosing depends on regimen)

---

1) What it’s used for (2024 indications)

Ibrance is used for hormone receptor–positive (HR+), HER2-negative breast cancer, often in combination with endocrine therapy.

Typical approved settings (may vary by region and individual patient factors):

• Advanced/metastatic HR+/HER2− breast cancer
  
  • With an aromatase inhibitor (e.g., letrozole/anastrozole) in postmenopausal patients (and in some situations men or pre/perimenopausal women with ovarian suppression).
    
  • With fulvestrant in patients with disease progression after endocrine therapy.
    
• Certain adjuvant/early-stage high-risk contexts have also been studied and may have regulatory approvals depending on local guidance and trial results.
  
  

  If you tell me your country/region and the exact disease stage, I can align the profile to the most relevant label/regulatory status.
  
  ---
  
  

  2) How it works
  

  Palbociclib inhibits CDK4/6, which helps halt cell-cycle progression from the G1 to S phase. In HR+/HER2− breast cancer, this can enhance the effect of endocrine therapy.
  
  ---
  
  

  3) Dosage & administration (typical adult dosing)
  

  Common approach in clinical practice:
  

• Given orally once daily for 21 days, then 7 days off (28-day cycle),
  
• With an endocrine agent (aromatase inhibitor or fulvestrant depending on the setting).
  
  Starting dose depends on regimen and label; commonly:
  
• 125 mg PO daily for 21 days on/7 off
  
  Dose reductions are typically used for toxicity (especially neutropenia).
  

  Exact dosing should follow the prescribing information and your clinician’s plan, because renal/hepatic impairment and drug interactions can change recommendations.
  
  ---
  
  

  4) Key safety information (most important)
  

  The most notable adverse effect
  

• Neutropenia (often the most common dose-limiting toxicity)
  
  Monitoring:
  
• CBC (complete blood count) prior to starting and regularly during treatment.
  
• Many regimens require checks at the start of each cycle and/or more frequently early on.
  
  

  Other common side effects
  

• Infections (especially if neutropenia occurs)
  
• Fatigue
  
• Nausea
  
• Anemia
  
• Thrombocytopenia (less common than neutropenia)
  
• Stomatitis/mouth sores
  
• Diarrhea
  
• Increased liver enzymes (AST/ALT) in some patients
  
  ---
  
  

  5) Drug interactions (important)
  

  Palbociclib is associated with interactions involving CYP3A metabolism.
  
  Major interaction considerations:
  

• Strong CYP3A inhibitors can increase palbociclib exposure → higher toxicity risk.
  
• Strong CYP3A inducers can reduce palbociclib exposure → reduced efficacy.
  
  Always review:
  
• Prescription meds (including antifungals/antibiotics)
  
• OTC drugs
  
• Supplements (some can be enzyme-active)
  
  ---
  
  

  6) Special populations
  

• Hepatic impairment: dose adjustments may be needed depending on severity.
  
• Renal impairment: guidance varies; clinician must choose dose appropriately.
  
• Pregnancy: avoid; effects on fetus are expected based on mechanism—use contraception per label/oncologist guidance.
  
• Elderly: generally similar principles; monitor closely for cytopenias and tolerability.
  
  ---
  
  

  7) Resistance / clinical notes (practical)
  

• Response is usually best in HR+/HER2− disease and typically in combination with endocrine therapy.
  
• Cytopenias are often manageable with monitoring and dose holds/reductions.
  
• Ongoing assessment for disease progression and tolerability is standard.
  
  ---
  
  

  8) What labs/monitoring are typically required
  

  At minimum, clinicians usually monitor:
  

• CBC with differential (neutrophils)
  
• Liver function tests (AST/ALT, bilirubin as indicated)
  
• Additional labs as appropriate (e.g., electrolytes) depending on symptoms and comedications
  
  ---
  
  

  9) When to seek urgent help
  

  Contact a clinician urgently or seek emergency care for:
  

• Fever (especially with known neutropenia)
  
• Signs of severe infection
  
• Severe bleeding/bruising
  
• Significant shortness of breath, chest pain, or other severe symptoms (to rule out complications)
  
  ---
  
  

  Quick summary
  

  Ibrance (palbociclib) is an oral CDK4/6 inhibitor for HR+/HER2− breast cancer, commonly with endocrine therapy. The major toxicity is neutropenia, so frequent CBC monitoring and dose adjustments are key.
  
  ---
  
  If you want, tell me:
  

1. your cancer setting (metastatic? adjuvant? combination partner like letrozole/fulvestrant?),
   
2. your age/sex, and
   
3. any liver/kidney issues or current meds,
   and I’ll tailor the 2024 drug profile (dosing strategy, monitoring schedule, and interaction hotspots) to your situation.